CN108686005A - 一种治疗银屑病的医药组合物及其使用方法 - Google Patents
一种治疗银屑病的医药组合物及其使用方法 Download PDFInfo
- Publication number
- CN108686005A CN108686005A CN201810845266.4A CN201810845266A CN108686005A CN 108686005 A CN108686005 A CN 108686005A CN 201810845266 A CN201810845266 A CN 201810845266A CN 108686005 A CN108686005 A CN 108686005A
- Authority
- CN
- China
- Prior art keywords
- parts
- component
- psoriasis
- dyers
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 20
- 241000219094 Vitaceae Species 0.000 claims abstract description 52
- 235000021021 grapes Nutrition 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 41
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000470 constituent Substances 0.000 claims abstract description 20
- 235000012907 honey Nutrition 0.000 claims abstract description 17
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 16
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 16
- 229960003237 betaine Drugs 0.000 claims abstract description 15
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 15
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 11
- 241000931705 Cicada Species 0.000 claims abstract description 11
- 241000594394 Hedyotis Species 0.000 claims abstract description 11
- 241000123069 Ocyurus chrysurus Species 0.000 claims abstract description 11
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 239000010231 banlangen Substances 0.000 claims abstract description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 206010037575 Pustular psoriasis Diseases 0.000 claims abstract description 7
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 7
- 229960001631 carbomer Drugs 0.000 claims abstract description 7
- 241000118841 Lithospermum incisum Species 0.000 claims abstract 3
- 238000000605 extraction Methods 0.000 claims description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 239000007788 liquid Substances 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 17
- 210000000481 breast Anatomy 0.000 claims description 15
- 235000015927 pasta Nutrition 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 10
- 238000007598 dipping method Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 238000010792 warming Methods 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 240000007643 Phytolacca americana Species 0.000 claims 1
- 235000009074 Phytolacca americana Nutrition 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 11
- 244000157790 Buglossoides arvense Species 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- -1 filtering Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 240000008821 Menyanthes trifoliata Species 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 235000004443 Ricinus communis Nutrition 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000008159 sesame oil Substances 0.000 description 5
- 235000011803 sesame oil Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- QQGISFDJEJMKIL-JAIQZWGSSA-N (5z)-5-[[3-(hydroxymethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical group C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1CO QQGISFDJEJMKIL-JAIQZWGSSA-N 0.000 description 1
- QBYSPFYUVWFCBF-UHFFFAOYSA-N 1,4-dimethylpiperidin-1-ium-4-carboxylate Chemical compound CN1CCC(C)(C(O)=O)CC1 QBYSPFYUVWFCBF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000251123 Mustelus antarcticus Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000132171 Phryma leptostachya Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000010132 annular erythema Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229930193249 esculentoside Natural products 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000027498 hoarse voice Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000014239 psoriasis 11 Diseases 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940063138 sporanox Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗银屑病的医药组合物及其使用方法,涉及医药技术领域,包括美洲商陆提取物、A组分和B组分,所述A组分包括以下重量份数的组成成分:蛇床子30‑40份、马齿笕30‑40份、蝉蜕10‑18份、苦参6‑12份、茯苓6‑12份、三七4‑10份、当归4‑10份、紫草4‑10份、茜草1‑5份、蛇舌草1‑5份、板蓝根1‑5份,所述B组分包括以下重量份数的组成成分:蜂蜜5‑10份、水杨酸10‑20份、甜菜碱1‑2份、丁二醇0.1‑1份、聚甘油8‑12份、1,2‑戊二醇0.1‑1份、氢化蓖麻油0.1‑1份、三乙醇胺0.1‑0.5份、卡波姆0.1‑0.5份、水40‑50份,本发明可以有效治愈寻常型银屑病和脓疱型银屑病。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种治疗银屑病的医药组合物及其使用方法。
背景技术
银屑病俗称牛皮癣,是一种慢性多发性皮肤病,常有家族发病史,有遗传倾向。其特征性损害为红色丘疹或斑块上覆有多层银白色鳞屑。其皮肤损害的形态学变异极大,可表现为斑丘疹,环状红斑,红皮病,脓疱等,伴有瘙痒,严重影响人们的生活质量。男女老少皆可罹患,多见于青壮年,男略多于女。银屑病的诱发因素中,除了家族的遗传因素外,细菌感染也是不容忽视的因素,另外近年来,研究发现,精神紧张,劳累等因素也会导致银屑病的发生,该病在临床上屡见不鲜,往往给患者造成极大的精神压力及痛苦。
银屑病属于慢性反复性皮肤病,治疗时间比较长,目前治疗银屑病的内用药物大多属于免疫抑制剂类如斯皮仁诺、卡泊三醇,对正常的免疫功能会有不良影响,而且短期内见效很快,但是用过一段时间后,疗效就会大大折扣,如果盲目长期用药,会使银屑病患者的抵抗力低下,严重影响治疗。
中药药浴对银屑病的治疗也有一定的效果,《朱仁康临床经验集》中记载以下几贴方剂都可以用于银屑病的治疗:
醋泡方:荆芥18g、防风18g、红花18g、地骨皮18g、皂角30g、大枫子30g、明矾18g,湿敷、局部浸浴,主治鹅掌风(手癣)。
疣洗方:马齿苋60g、蜂房9g、陈皮15g、苍术15g、细辛9g、蛇床子9g、白芷9g、苦参15g、湿敷,主治扁平疣。
脂溢洗方:苍耳子30g、苦参15g、王不留行30g、明矾9g、湿敷、局部熏洗,主治头皮脂溢性皮炎。
止痒洗方:软坚止痒,透骨草30g、红花15g、苦参30g、雄黄15g、明矾15g、湿敷,局部熏洗,主治神经性皮炎、皮肤淀粉样变病。
经过实际验证,这些方剂的治疗效果都很有限,往往只能起到短暂控制的效果,短则2周,长则半年又会复发。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明提供了一种治疗银屑病的医药组合物及其使用方法。
(二)技术方案
为实现以上目的,本发明通过以下技术方案予以实现:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分,所述A组分包括以下重量份数的组成成分:蛇床子30-40份、马齿笕30-40份、蝉蜕10-18份、苦参6-12份、茯苓6-12份、三七4-10份、当归4-10份、紫草4-10份、茜草1-5份、蛇舌草1-5份、板蓝根1-5份,所述B组分包括以下重量份数的组成成分:蜂蜜5-10份、水杨酸10-20份、甜菜碱1-2份、丁二醇0.1-1份、聚甘油8-12份、1,2-戊二醇0.1-1份、氢化蓖麻油0.1-1份、三乙醇胺0.1-0.5份、卡波姆0.1-0.5份、水40-50份。
优选地,包括美洲商陆提取物、A组分和B组分,所述A组分包括以下重量份数的组成成分:蛇床子32份、马齿笕35份、蝉蜕15份、苦参10份、茯苓10份、三七5份、当归5份、紫草6份、茜草4份、蛇舌草2份、板蓝根4份,所述B组分包括以下重量份数的组成成分:蜂蜜6份、水杨酸13份、甜菜碱1.6份、丁二醇0.4份、聚甘油10份、1,2-戊二醇0.5份、氢化蓖麻油0.5份、三乙醇胺0.2份、卡波姆0.2份、水45份。
优选地,所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,烘干并粉碎,再放入萃取釜中,进行超临界CO2萃取,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物。
优选地,所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为15-20L/h,萃取时间为3-5h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物。
优选地,所述氢化蓖麻油为PEG-40氢化蓖麻油、PEG-60氢化蓖麻油、PEG-80氢化蓖麻油中的任意一种。
优选地,所述聚甘油为聚甘油-3、聚甘油-6、聚甘油-10中的任意一种。
优选地,所述B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,100-120r/min搅拌30-50min后,再升温至40-50℃加入聚甘油、1,2-戊二醇、氢化蓖麻油,150-200r/min搅拌60-80min,最后加入三乙醇胺,200-250r/min搅拌10-20min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制40-60min,期间适量加水,过滤,待滤液冷却至40-45℃时加入美洲商陆提取物,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持3-5h;
(3)患者进入浸泡药液中,药浴1-2h。
优选地,组分A与美洲商陆提取物的重量比为10-15:1。
本发明治疗银屑病的医药组合物,适用于治疗寻常型银屑病和脓疱型银屑病。
本发明中各中药成分功效和作用机理:
蛇床子,味辛、苦,性温,归肾经,燥湿祛风,杀虫止痒,温肾壮阳,主治阴痒带下,湿疹瘙痒,湿痹腰痛,肾虚阳痿,宫冷不孕。
马齿笕,酸,寒,归肝、大肠经,清热解毒,凉血止血,主治止痢,热毒血痢,痈肿疔疮,湿疹,丹毒,蛇虫咬伤,便血,痔血,崩漏下血。
蝉蜕,味甘、咸,性凉。归肺、肝经。疏散风热,利咽开音,透疹,明目退翳,息风止痉。主治风热感冒,温病初起,咽痛音哑,麻疹不透,风疹瘙痒,目赤翳障,急慢惊风,破伤风证,小儿夜啼不安。
苦参,味苦,性寒。归心、肝、胃、大肠、膀胱经。清热燥湿,杀虫,利尿。主治热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风,外治滴虫性阴道炎。
茯苓,味甘、淡,性平。归心、肺、脾、肾经。利水渗湿,健脾,宁心。主治水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。
三七,甘、微苦,温。归肝、胃经。散瘀止血,消肿定痛。主治咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛。
当归,味甘、辛,性温。归肝、心、脾经。补血活血,调经止痛,润肠通便。主治用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,风湿痹痛,跌扑损伤,痈疽疮疡,肠燥便秘。酒当归活血通经。用于经闭痛经,风湿痹痛,跌扑损伤。
紫草,甘、咸,寒,凉血,活血,解毒透疹。主治血热毒盛,斑疹紫黑,麻疹不透,疮疡,湿疹,水火烫伤,温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。
茜草,苦,寒。归肝经。凉血活血,祛瘀,通经。用于吐血、衄血、崩漏下血、外伤出血、经闭瘀阻、关节痹痛、跌扑肿痛。凉血止血,活血祛瘀。
蛇舌草,甘,苦,寒,入胃、大肠、小肠经。清热解毒,消痈散结,利尿除湿。用于肠痈、肺痈、疮疖肿痛、毒蛇咬伤。肠痈、肺痈,湿热水肿、热淋、黄疸。
板蓝根,苦,寒。归心、胃经。清热解毒,凉血,利咽。主治温疫时毒,发热咽痛,温毒发斑,痄腮,烂喉丹痧,大头瘟疫,丹毒,痈肿。
(三)有益效果
本发明提供了一种治疗银屑病的医药组合物及其使用方法,具有以下有益效果:
目前对美洲商陆的化学成分和药理作用研究较为清楚的是商陆皂苷类成分,对其进行提取后,具有消炎、抗菌、增强免疫等作用,但是目前也有误食中毒的相关报道,本发明中预先对美洲商陆叶子中的有效成分进行超临界CO2萃取提取,可以最大保持其活性,避免其中有效成分的变质失活;加入到A组分的复配中药配方中对患者进行药浴浸泡对于寻常型银屑病和脓疱型银屑病具有良好的治疗效果,治标更治本,治疗效果优于传统的西医和中医治疗;患者预先用乳膏状的B组分涂抹全身,可以软化皮肤白屑、硬壳,滋养皮肤,也便于后续药浴浸泡时药力进入皮肤底层,起到好的治疗效果。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分;
所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为18L/h,萃取时间为4.5h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物;
所述A组分包括以下重量份数的组成成分:蛇床子32份、马齿笕35份、蝉蜕15份、苦参10份、茯苓10份、三七5份、当归5份、紫草6份、茜草4份、蛇舌草2份、板蓝根4份;
所述B组分包括以下重量份数的组成成分:蜂蜜6份、水杨酸13份、甜菜碱1.6份、丁二醇0.4份、聚甘油-3 10份、1,2-戊二醇0.5份、PEG-40氢化蓖麻油0.5份、三乙醇胺0.2份、卡波姆0.2份、水45份;
B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,110r/min搅拌45min后,再升温至45℃加入聚甘油-3、1,2-戊二醇、PEG-40氢化蓖麻油,180r/min搅拌65min,最后加入三乙醇胺,220r/min搅拌15min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制50min,期间适量加水,过滤,待滤液冷却至42℃时加入美洲商陆提取物,组分A与美洲商陆提取物的重量比为12:1,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持3.5h;
(3)患者进入浸泡药液中,药浴1.6h。
实施例2:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分;
所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为15L/h,萃取时间为4h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物;
所述A组分包括以下重量份数的组成成分:蛇床子32份、马齿笕30份、蝉蜕16份、苦参8份、茯苓10份、三七5份、当归6份、紫草5份、茜草2份、蛇舌草2份、板蓝根1份;
所述B组分包括以下重量份数的组成成分:蜂蜜8份、水杨酸15份、甜菜碱1.5份、丁二醇0.2份、聚甘油-6 8份、1,2-戊二醇0.4份、PEG-60氢化蓖麻油0.5份、三乙醇胺0.4份、卡波姆0.3份、水44份;
B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,120r/min搅拌45min后,再升温至50℃加入聚甘油-6、1,2-戊二醇、PEG-60氢化蓖麻油,180r/min搅拌65min,最后加入三乙醇胺,220r/min搅拌12min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制60min,期间适量加水,过滤,待滤液冷却至43℃时加入美洲商陆提取物,组分A与美洲商陆提取物的重量比为10:1,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持4h;
(3)患者进入浸泡药液中,药浴2h。
实施例3:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分;
所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为15L/h,萃取时间为3h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物;
所述A组分包括以下重量份数的组成成分:蛇床子30份、马齿笕30份、蝉蜕10份、苦参6份、茯苓6份、三七4份、当归4份、紫草4份、茜草1份、蛇舌草1份、板蓝根1份;
所述B组分包括以下重量份数的组成成分:蜂蜜5份、水杨酸10份、甜菜碱1份、丁二醇0.1份、聚甘油-10 8份、1,2-戊二醇0.1份、PEG-80氢化蓖麻油0.1份、三乙醇胺0.1份、卡波姆0.1份、水40份;
B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,100r/min搅拌30min后,再升温至40℃加入聚甘油-10、1,2-戊二醇、PEG-80氢化蓖麻油,150r/min搅拌60min,最后加入三乙醇胺,200r/min搅拌10min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制40min,期间适量加水,过滤,待滤液冷却至40℃时加入美洲商陆提取物,组分A与美洲商陆提取物的重量比为10:1,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持3h;
(3)患者进入浸泡药液中,药浴1h。
实施例4:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分;
所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为20L/h,萃取时间为5h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物;
所述A组分包括以下重量份数的组成成分:蛇床子40份、马齿笕40份、蝉蜕18份、苦参12份、茯苓12份、三七10份、当归10份、紫草10份、茜草5份、蛇舌草5份、板蓝根5份;
所述B组分包括以下重量份数的组成成分:蜂蜜10份、水杨酸20份、甜菜碱2份、丁二醇1份、聚甘油-6 12份、1,2-戊二醇1份、PEG-40氢化蓖麻油1份、三乙醇胺0.5份、卡波姆0.5份、水50份;
B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,120r/min搅拌50min后,再升温至50℃加入聚甘油-6、1,2-戊二醇、PEG-40氢化蓖麻油,200r/min搅拌80min,最后加入三乙醇胺,250r/min搅拌20min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制60min,期间适量加水,过滤,待滤液冷却至45℃时加入美洲商陆提取物,组分A与美洲商陆提取物的重量比为15:1,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持5h;
(3)患者进入浸泡药液中,药浴2h。
实施例5:
一种治疗银屑病的医药组合物,包括美洲商陆提取物、A组分和B组分;
所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为20L/h,萃取时间为5h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物;
所述A组分包括以下重量份数的组成成分:蛇床子32份、马齿笕33份、蝉蜕16份、苦参8份、茯苓10份、三七6份、当归5份、紫草5份、茜草2份、蛇舌草3份、板蓝根4份;
所述B组分包括以下重量份数的组成成分:蜂蜜6份、水杨酸13份、甜菜碱1.5份、丁二醇0.2份、聚甘油-3 8份、1,2-戊二醇0.1份、PEG-80氢化蓖麻油1份、三乙醇胺0.5份、卡波姆0.3份、水50份;
B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,120r/min搅拌40min后,再升温至45℃加入聚甘油-3、1,2-戊二醇、PEG-80氢化蓖麻油,180r/min搅拌80min,最后加入三乙醇胺,250r/min搅拌10min,得到乳膏状的B组分。
上述治疗银屑病的医药组合物的使用方法,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制40min,期间适量加水,过滤,待滤液冷却至45℃时加入美洲商陆提取物,组分A与美洲商陆提取物的重量比为11:1,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持3.5h;
(3)患者进入浸泡药液中,药浴2h。
临床实验:
两组共200例,均为门诊患者;
其中实验组100例,其中男76例,女24例,年龄最小12岁,最大53岁,平均31岁,病程最短5周,最长12年,其中寻常型银屑病49例,脓疱型银屑病51例;
对照组100例,其中男80例,女20例,年龄最小10岁,最大52岁,平均30岁,病程最短4周,最长10年,其中寻常型银屑病50例,脓疱型银屑病50例;
两组一般情况及病情轻重均无显著差异,具有可比性。
实验组使用本发明实施例1医药组合物进行治疗,每三天一次;
对照组:口服复方甘草酸苷片(日本美能发源制药公司生产)和维生素A软胶囊(国药控股星鲨制药(厦门)有限公司生产),一天三次、外涂恩博克(大连亚维药业有限公司生产),一天一次;
两组均以1月为一疗程,治疗三个疗程后判断疗效。
疗效标准(参考《中医病症诊断疗效标准》)
临床痊愈:皮损全部消退,或遗留色素沉着斑。
显效:皮损消退≥70%;
有效:皮损消退30%-69%
无效:皮损消退<30%或无变化或加重。
临床实验结果如下表1所示:
表1:
一年后分别对实验组治疗痊愈的93位患者和对照组治疗痊愈的66位患者进行回访,其中实验组治疗痊愈的93位患者无人复发,而对照组治疗痊愈的66位患者有8位复发。
对两组疗效进行比较,经过Ridit检验,实验组疗效明显优于对照组(p<0.05)。
典型病例:
患者徐某,男,35岁,背部大片鳞屑斑伴瘙痒2月余,按过敏性皮炎治疗2周后无效,鳞屑斑范围逐渐扩大,瘙痒加重,患者精神不佳,睡眠质量差,舌苔暗红,经过西医诊断为银屑病,后经过本发明医药组合物连续治疗1个月,背部鳞屑斑明显减少,瘙痒减轻,精神及睡眠亦较前有所好转,继续治疗2个月后,患者完全恢复正常,半年后随访银屑病未复发。
患者张某某,女,50岁,三年前患银屑病,之后西药治疗痊愈,近月来因使用喷剂擦油烟机后,银屑病复发脸部、颈部皮损严重,口服地塞米松、抗生素等均无效,后经过本发明医药组合物连续治疗2个月,病情缓解,脸部、颈部皮损明显减少,继续治疗2个月后,完全恢复正常,半年后随访银屑病未复发。
患者谷某,男,19岁,长期工作于阴冷潮湿的环境中,四肢开始出现皮疹,后扩散至前胸后背,伴有瘙痒,挠后出现破皮出血,就诊于不少大医院,诊断为“银屑病”,予以口服和外用药物(具体不详)治疗,病情得到控制但是始终未痊愈,之后某次剧烈运动后冷水洗澡,导致病情加重,四肢可见散在红色斑片,挠后有大片皮屑退掉,出血,后经过本发明医药组合物连续治疗1个月,病情得到控制,红色斑片变淡,面积缩小,继续治疗3个月后,完全痊愈,半年后随访银屑病未复发。
患者胡某,女,26岁,患上银屑病11年,全国皮肤病医院都看过,多方治疗效果不佳,近半年病情加重,全身白屑满布,皮硬且坚,瘙痒,消瘦乏力,食欲较差,经过本发明医药组合物连续治疗1个月,白屑脱落、硬壳变薄,皮肤稍软,病情得到控制,继续治疗1个月后,白屑脱净,精神好转,食欲转佳,再继续治疗1个月后,完全痊愈,半年后随访银屑病未复发。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括所述要素的过程、方法、物品或者设备中还存在另外的相同要素。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.一种治疗银屑病的医药组合物,其特征在于,包括美洲商陆提取物、A组分和B组分,所述A组分包括以下重量份数的组成成分:蛇床子30-40份、马齿笕30-40份、蝉蜕10-18份、苦参6-12份、茯苓6-12份、三七4-10份、当归4-10份、紫草4-10份、茜草1-5份、蛇舌草1-5份、板蓝根1-5份,所述B组分包括以下重量份数的组成成分:蜂蜜5-10份、水杨酸10-20份、甜菜碱1-2份、丁二醇0.1-1份、聚甘油8-12份、1,2-戊二醇0.1-1份、氢化蓖麻油0.1-1份、三乙醇胺0.1-0.5份、卡波姆0.1-0.5份、水40-50份。
2.如权利要求1所述的治疗银屑病的医药组合物,其特征在于,包括美洲商陆提取物、A组分和B组分,所述A组分包括以下重量份数的组成成分:蛇床子32份、马齿笕35份、蝉蜕15份、苦参10份、茯苓10份、三七5份、当归5份、紫草6份、茜草4份、蛇舌草2份、板蓝根4份,所述B组分包括以下重量份数的组成成分:蜂蜜6份、水杨酸13份、甜菜碱1.6份、丁二醇0.4份、聚甘油10份、1,2-戊二醇0.5份、氢化蓖麻油0.5份、三乙醇胺0.2份、卡波姆0.2份、水45份。
3.如权利要求1所述的治疗银屑病的医药组合物,其特征在于,所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,烘干并粉碎,再放入萃取釜中,进行超临界CO2萃取,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物。
4.如权利要求3所述的治疗银屑病的医药组合物,其特征在于,所述美洲商陆提取物的制备方法为:将美洲商陆采收后取下叶子,于烘箱中60℃烘干并粉碎,再放入萃取釜中,待制冷装置与萃取釜和加热装置正常工作后,打开压缩泵加压至所需压力,调整CO2流量,进行超临界CO2萃取,萃取时固定分离压力4MPa,萃取压力为30MPa,萃取温度为50℃,CO2流量为15-20L/h,萃取时间为3-5h,萃取后收集分离釜中的液体,加水、二氯甲烷萃取后分液,二氯甲烷相减压浓缩后干燥即可得到所述美洲商陆提取物。
5.如权利要求1所述的治疗银屑病的医药组合物,其特征在于,所述氢化蓖麻油为PEG-40氢化蓖麻油、PEG-60氢化蓖麻油、PEG-80氢化蓖麻油中的任意一种。
6.如权利要求1所述的治疗银屑病的医药组合物,其特征在于,所述聚甘油为聚甘油-3、聚甘油-6、聚甘油-10中的任意一种。
7.如权利要求1所述的治疗银屑病的医药组合物,其特征在于,所述B组分的制备方法为:按比例称取原料,依次将将蜂蜜、水杨酸、甜菜碱、丁二醇加入到水中,100-120r/min搅拌30-50min后,再升温至40-50℃加入聚甘油、1,2-戊二醇、氢化蓖麻油,150-200r/min搅拌60-80min,最后加入三乙醇胺,200-250r/min搅拌10-20min,得到乳膏状的B组分。
8.如权利要求1所述的治疗银屑病的医药组合物的使用方法,其特征在于,包括以下步骤:
(1)将组分A加入到40倍与其重量的水中,大火煮沸后,转小火熬制40-60min,期间适量加水,过滤,待滤液冷却至40-45℃时加入美洲商陆提取物,保温搅拌,得到浸泡药液;
(2)患者周身清洗干燥后,涂抹乳膏状的B组分,保持3-5h;
(3)患者进入浸泡药液中,药浴1-2h。
9.如权利要求1所述的治疗银屑病的医药组合物的使用方法,其特征在于,组分A与美洲商陆提取物的重量比为10-15:1。
10.如权利要求1-7中任一项所述的治疗银屑病的医药组合物,适用于治疗寻常型银屑病和脓疱型银屑病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845266.4A CN108686005A (zh) | 2018-07-27 | 2018-07-27 | 一种治疗银屑病的医药组合物及其使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810845266.4A CN108686005A (zh) | 2018-07-27 | 2018-07-27 | 一种治疗银屑病的医药组合物及其使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108686005A true CN108686005A (zh) | 2018-10-23 |
Family
ID=63851786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810845266.4A Pending CN108686005A (zh) | 2018-07-27 | 2018-07-27 | 一种治疗银屑病的医药组合物及其使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108686005A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109260355A (zh) * | 2018-11-23 | 2019-01-25 | 上海松皓生物科技有限公司 | 一种治疗和改善银屑病的组合物和制备方法与应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1137413A (zh) * | 1996-04-05 | 1996-12-11 | 李国雄 | 一种治疗牛皮癣的药物——愈癣丸 |
CN1262950A (zh) * | 1999-02-10 | 2000-08-16 | 徐守宏 | 林菌沙 |
CN101757380A (zh) * | 2008-10-14 | 2010-06-30 | 赵赐安 | 一种治疗牛皮癣的复方内服散剂 |
CN102309627A (zh) * | 2010-06-30 | 2012-01-11 | 丰建萍 | 一种治疗牛皮癣的中药组合物 |
CN102370918A (zh) * | 2011-11-17 | 2012-03-14 | 中国中医科学院中医临床基础医学研究所 | 一种治疗牛皮癣的中药复方制剂及其制备方法 |
CN102552761A (zh) * | 2012-03-23 | 2012-07-11 | 王永臻 | 一种治疗牛皮癣病的中药丸剂 |
CN103877248A (zh) * | 2014-04-02 | 2014-06-25 | 安雅杰 | 药物组合物和药物制剂及其制备方法以及它们的应用 |
CN103877443A (zh) * | 2012-12-19 | 2014-06-25 | 张显云 | 一种治疗神经性皮炎混合浓缩液 |
CN105853842A (zh) * | 2015-01-23 | 2016-08-17 | 孙典全 | 治疗牛皮癣的中药方 |
CN107496195A (zh) * | 2017-08-01 | 2017-12-22 | 杭州惠博士健康产业有限公司 | 一种重组人透明质酸组合物及其在化妆品中的应用 |
-
2018
- 2018-07-27 CN CN201810845266.4A patent/CN108686005A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1137413A (zh) * | 1996-04-05 | 1996-12-11 | 李国雄 | 一种治疗牛皮癣的药物——愈癣丸 |
CN1262950A (zh) * | 1999-02-10 | 2000-08-16 | 徐守宏 | 林菌沙 |
CN101757380A (zh) * | 2008-10-14 | 2010-06-30 | 赵赐安 | 一种治疗牛皮癣的复方内服散剂 |
CN102309627A (zh) * | 2010-06-30 | 2012-01-11 | 丰建萍 | 一种治疗牛皮癣的中药组合物 |
CN102370918A (zh) * | 2011-11-17 | 2012-03-14 | 中国中医科学院中医临床基础医学研究所 | 一种治疗牛皮癣的中药复方制剂及其制备方法 |
CN102552761A (zh) * | 2012-03-23 | 2012-07-11 | 王永臻 | 一种治疗牛皮癣病的中药丸剂 |
CN103877443A (zh) * | 2012-12-19 | 2014-06-25 | 张显云 | 一种治疗神经性皮炎混合浓缩液 |
CN103877248A (zh) * | 2014-04-02 | 2014-06-25 | 安雅杰 | 药物组合物和药物制剂及其制备方法以及它们的应用 |
CN105853842A (zh) * | 2015-01-23 | 2016-08-17 | 孙典全 | 治疗牛皮癣的中药方 |
CN107496195A (zh) * | 2017-08-01 | 2017-12-22 | 杭州惠博士健康产业有限公司 | 一种重组人透明质酸组合物及其在化妆品中的应用 |
Non-Patent Citations (2)
Title |
---|
王锦鸿,陈仁寿主编: "《临床实用中药辞典》", 30 November 2003, 金盾出版社 * |
田普永: "商陆的药理作用及临床应用 ", 《西北药学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109260355A (zh) * | 2018-11-23 | 2019-01-25 | 上海松皓生物科技有限公司 | 一种治疗和改善银屑病的组合物和制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520655B (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN108042770A (zh) | 治疗肾炎的中药熏洗剂、其制备方法和使用方法 | |
CN108014183A (zh) | 一种治疗烧烫创伤的药物 | |
CN104524481B (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN108686005A (zh) | 一种治疗银屑病的医药组合物及其使用方法 | |
CN105535822A (zh) | 治疗痔疮的中药组合物及其制备方法 | |
CN104324261A (zh) | 治疗高血糖的药物组合物及其制备方法 | |
CN106038995A (zh) | 一种用于治疗口周皮炎的中药冲剂及制备方法 | |
CN105535839A (zh) | 一种治疗结肠癌的中药片剂及其制备方法 | |
CN101411769A (zh) | 治疗脚气病的药物及其制备方法 | |
CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
CN105031170A (zh) | 一种保健足浴粉及其制备方法 | |
CN104225256A (zh) | 一种治疗火毒内陷型烧伤的中药及制备方法 | |
CN104606571A (zh) | 一种生津止渴鲜菠菜根代茶饮及制备方法 | |
CN109893622A (zh) | 一种新生儿黄疸的中药外洗方 | |
CN108310255A (zh) | 一种治疗湿疹的中药浴渍制剂及其制备方法 | |
CN103417669B (zh) | 一种治疗腹痛、腹泻的药物 | |
CN106880758A (zh) | 一种用于外阴瘙痒和湿疹皮炎顽癣的中药制剂及制备方法 | |
CN103285182B (zh) | 一种治疗皮肤病的外用药膏及制备方法 | |
CN110478420B (zh) | 一种户外防护油及其制备方法 | |
CN105596461A (zh) | 一种治疗乳腺炎的中药及其制备方法 | |
CN105381366A (zh) | 一种治疗褥疮的中药组合物及其制备方法 | |
CN105560582A (zh) | 治疗冻疮的消肿止痒药膏及制法 | |
CN105597068A (zh) | 一种用于治疗过敏性鼻炎的中药制剂及制备方法 | |
CN104707029B (zh) | 一种治疗银屑病的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210825 Address after: 2-168 Xuetang Road, Mingguang City, Chuzhou City, Anhui Province 239400 Applicant after: Mao Li Address before: 242200 No.10 Yuanwu, Wuhe village, Yangtan Township, Guangde County, Xuancheng City, Anhui Province Applicant before: Zhang Lilan |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
RJ01 | Rejection of invention patent application after publication |